Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 08/11/2020.
  • Additional Information
    • Alternate Title:
      ROMARK-COVID19
    • Subject Terms:
      Florida
    • Abstract:
      TAMPA, Fla., Aug. 11, 2020 /PRNewswire/ -- Romark, a research-based pharmaceutical company focused on the discovery, development and delivery of innovative new medicines, primarily in the field of infectious diseases, announced today the initiation of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19. [ABSTRACT FROM PUBLISHER]